Transdermal delivery of 4-hydroxytamoxifen decreased Ki-67 expression, the primary study endpoint, in DCIS lesions and resulted in tumor adjacent mammary tissue drug levels comparable to patients receiving oral therapy (5.8 versus 5.4 ng/g, respectively). Here, MKI67 is linked to neoplasm.